Facebook
X
LinkedIn
ForwardThe Journey of the Unknown Primary in the HPV Era: Evaluation, Treatment, Surveillance and Management of Oligometastatic Disease (PRO 08)
Management of unknown primary head and neck squamous cell carcinomas has evolved as the incidence of p16 positive disease among head and neck cancer patients has increased. This activity discusses the diagnostic steps to identify a primary site and treatment of patients where primary is and is not identified. We also discuss post-treatment surveillance of p16 positive patients including the role of TTMV-HPV DNA as a surveillance tool. Finally, we discuss management options for patients with oligometastatic disease.
Target Audience
This activity is designed to meet the interests of medical oncologists, radiation oncologists, radiation physicists, nurses, radiation therapists, radiation dosimetrists, residents and specialists
Learning Objectives
Upon completion of this activity, participants should be able to do the following:
- Explain the steps in evaluation of a patient with an unknown primary p16 positive head and neck squamous cell carcinoma and management of patients where primary site is not identified.
- Discuss the role of TTMV-HPV DNA as a surveillance tool for patients with p16 positive head and neck squamous cell carcinoma.
- Describe management options for patients with oligometastatic p16 positive head and neck squamous cell carcinoma.
- Sean Philip Collins, MD, PhD, is employed by MedStar Georgetown University Hospital.
- Nicholas van As, MD, MB, is employed by The Royal Marsden NHS Foundation Trust.
- Jonathan Andrew Haas, MD, is employed by Perlmutter Cancer Center at New York University Langone Hospital - Long Island.
- Michael J. Zelefsky, MD, FASTRO, is employed by Memorial Sloan Kettering Cancer Center.
All relevant financial relationships have been mitigated.
The person(s) above served as the developer(s) of this activity. Additionally, the Annual Meeting Steering Committee had control over the content of this activity.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
Available Credit
- 1.25 AMA PRA Category 1 Credit™
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.